Marijuana and Bipolar Disorder: What You Need to Know

Bipolar disorder is one of the mental health conditions most sensitive to substance use. And cannabis, despite its widespread cultural reframing as low-risk, is one of the substances with the most consistently documented negative effect on bipolar course.

This is not a moralistic argument. It is a pharmacological one. The way THC interacts with the dopamine and endocannabinoid systems is specifically misaligned with the neurobiology of bipolar disorder in ways that matter clinically.

What This Page Covers

• What the research actually shows about cannabis and bipolar disorder
• How THC affects bipolar biology specifically
• The connection between cannabis use disorder and bipolar diagnosis risk
• How cannabis affects mood episode frequency and treatment response
• What to do if you use cannabis and have bipolar disorder
• What the research says about CBD
• How SiggyMD supports mood management

What the Prevalence Numbers Actually Show

People with bipolar disorder use cannabis at substantially higher rates than the general population. Approximately 20 percent of people with bipolar disorder meet criteria for cannabis use disorder, and comorbid substance use disorders are associated with earlier bipolar onset, higher hospitalization rates, and lower effectiveness of pharmacological treatment.

This high comorbidity rate is sometimes cited to argue that cannabis is simply correlated with, rather than causal of, bad bipolar outcomes. The bidirectionality is real. People in hypomanic states have lower impulse control and may initiate or escalate substance use. People with depression self-medicate with cannabis for temporary relief.

But the causal arrow also runs the other direction. A 2023 cohort study published in JAMA Psychiatry followed 6,651,765 individuals in Denmark and found that cannabis use disorder was independently associated with a significantly increased risk of both psychotic and nonpsychotic bipolar disorder, even after adjusting for confounders. The sustained increased risk observed up to 10 years after initial cannabis use disorder diagnosis supports the notion of a genuine causal association, not just detection bias.

The Biology of the Problem: Why THC and Bipolar Disorder Are a Poor Match

To understand why cannabis is particularly problematic for people with bipolar disorder, the pharmacology matters.

THC’s primary mechanism involves binding to CB1 receptors, which are concentrated in the prefrontal cortex, hippocampus, basal ganglia, and limbic system. This binding triggers dopamine release in the mesolimbic pathway, the brain’s reward and motivation system.

This is precisely where the problem lies. During manic phases, dopamine signaling is already dysregulated, with many researchers describing elevated dopaminergic activity as a central feature of mania. When THC is introduced, it can further increase dopamine levels, potentially intensifying manic symptoms including heightened excitement, impulsivity, and reduced need for sleep.

THC also disrupts the prefrontal regulatory circuits that provide brakes on impulsive and reward-seeking behavior, which are already compromised during hypomanic and manic states. The pharmacological effect of THC in a manic brain is not calming. It is often the opposite.

During depressive phases, the picture is more mixed but still problematic. Cannabis can provide temporary relief from depression, which explains part of the self-medication pattern. However, the dopaminergic blunting that follows regular THC exposure can worsen anhedonia during depressive episodes, and cannabis-induced changes in sleep architecture disrupt one of the most important mood stabilizers available: consistent sleep.

What Research Shows About Mood Episode Course

The effect of cannabis on bipolar disorder course, not just individual episodes, is one of the most important clinical considerations.

A systematic review and meta-analysis published in the Journal of Affective Disorders found that cannabis use may worsen the occurrence of manic symptoms in those diagnosed with bipolar disorder, and may act as a causal risk factor in the incidence of manic symptoms. The mean follow-up across studies was 3.9 years, providing longitudinal perspective.

A comprehensive 2024 systematic review published in Frontiers in Public Health analyzing 78 studies covering 1.9 million participants found that cannabis use is associated with increased depressive and manic symptoms in the general population, as well as an elevated likelihood of developing major depressive disorder and bipolar disorder.

Studies in bipolar populations specifically document that cannabis use contributes to longer mood episodes, increased mood cycling, lower remission rates, increased suicide risk, and lower recovery rates. These are not small marginal effects. They represent a meaningful acceleration of bipolar illness burden.

Cannabis, Medication Adherence, and Drug Interactions

The pharmacological interaction between cannabis and bipolar medications adds a layer of complexity that many patients and providers underestimate.

Common mood stabilizers and antipsychotics including lithium, valproate, lamotrigine, and quetiapine are processed by liver enzymes that THC and CBD also affect. Active compounds in marijuana, including THC and CBD, can interfere with these enzymes, potentially causing medication levels to reach dangerously high concentrations or fluctuate unpredictably in the bloodstream. Elevated mood stabilizer levels can produce toxicity. Insufficient levels can fail to prevent mood episodes.

Cannabis use is also associated with medication nonadherence in bipolar disorder, a finding documented in multiple large database analyses. Non-adherence to mood stabilizers is one of the strongest predictors of relapse and hospitalization.

The clinical implication is direct: any patient taking bipolar medication who also uses cannabis should disclose this to their prescriber, because dosing decisions depend on accurate medication level data that cannabis use can distort.

What About CBD?

CBD has received significant attention as a potentially safer alternative. The mechanism differs: CBD does not bind CB1 receptors with the same affinity as THC and does not produce the same psychotogenic or dopaminergic effects.

A pilot study examined CBD as adjunctive treatment for acute bipolar depression and found some signal of benefit. Early evidence suggests CBD may have anxiolytic properties relevant to bipolar comorbid anxiety.

However, the evidence base is preliminary, the effective dose for any psychiatric benefit appears to be higher than most commercial CBD products deliver, and high-dose CBD has significant drug interactions with many psychiatric medications including antipsychotics and anticonvulsants. CBD should never be used as a replacement for evidence-based bipolar treatment. Patients should discuss any CBD use with their prescriber before starting.

Harm Reduction When Cessation Is Not Immediate

If a patient with bipolar disorder uses cannabis and is not yet ready or able to stop, harm reduction is the appropriate clinical stance. This includes open discussion about the potential for harm, encouraging lower-frequency and lower-dose use if cessation is not an immediate option, avoiding high-THC products entirely, maintaining ongoing psychiatric care with full disclosure of cannabis use, and monitoring for any increase in mood episode frequency.

The goal of harm reduction is not to normalize continued use. It is to maintain clinical engagement while working toward the safest possible outcome.

About SiggyMD

For people managing anxiety and depression alongside bipolar disorder, consistent medication monitoring changes clinical outcomes. The daily check-in model at SiggyMD tracks mood patterns, sleep quality, and side effects continuously, providing the longitudinal data that quarterly appointments cannot capture.

“Cannabis use affects medication levels in ways that are not always obvious from symptom reports alone,” says Elizabeth Lokenauth, PA-C, of the SiggyMD clinical team. “When I have daily tracking data alongside a full substance use history, I can see when mood patterns shift in ways that correlate with use frequency, which gives me much more to work with than a reconstructed account from memory.”

SiggyMD currently treats anxiety and depression with clinician-supervised SSRIs and medication management. For bipolar disorder specifically, a comprehensive psychiatric evaluation is the appropriate starting point.

The anonymous intake requires no name, email, or account. A licensed prescriber reviews every treatment plan.

For more on related conditions, see bipolar disorder types and mood stabilizer medications. For context on depressive episodes, see what depression feels like.

If you are in crisis or experiencing thoughts of self-harm, call or text 988. If you are in immediate danger, call 911.

Start your anonymous intake with SiggyMD if co-occurring anxiety or depression is part of your picture.

What Members Are Saying

DK

D.K., 29

Bipolar II with Anxiety

“I used cannabis for years because it took the edge off my anxiety. What I didn’t connect was that my cycling was getting worse. Once my prescriber explained how THC was interacting with my mood stabilizer and made me track more carefully, I could actually see the pattern for myself. That was the turning point.”

MR

M.R., 37

Bipolar I

“Being honest with my prescriber about my cannabis use changed my care completely. The conversation I’d been avoiding for years was actually the most important one. Having a care team that doesn’t judge and does respond to the data made a real difference.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD currently manages anxiety and depression; bipolar-specific treatment requires a comprehensive psychiatric evaluation.

If you are in crisis or experiencing thoughts of self-harm, call or text 988. If you are in immediate danger, call 911.

Sources

1. Jefsen OH, Erlangsen A, Nordentoft M, Hjorthøj C. Cannabis Use Disorder and Subsequent Risk of Psychotic and Nonpsychotic Unipolar Depression and Bipolar Disorder. JAMA Psychiatry. 2023;80(8):803-810.

2. Sorkhou M, Dent S, George TP. Cannabis use and mood disorders: a systematic review. Frontiers in Public Health. 2024;12:1346207.

3. Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. Cannabis use and mania symptoms: a systematic review and meta-analysis. Journal of Affective Disorders. 2015;171:39-47.

4. ScienceDirect. Cannabis and tobacco use in bipolar disorder: Associations with early onset, psychotic symptoms, and relapse risk. Journal of Affective Disorders. 2025.

5. Psychology Today, Mondimore FM. Cannabis and Mood Disorders: Use at Your Own Risk. March 2025.

6. Cannaspecialists. Cannabis and Bipolar Disorder: Risks and Benefits. Accessed June 2026.